BHV-1300

Biohaven Ltd. has entered into a $600 million non-dilutive funding agreement with Oberland Capital, with an initial $250 million tranche expected by April 30, 2025.

Merida Biosciences has secured $121 million in Series A financing co-led by Bain Capital Life Sciences, BVF Partners, and Third Rock Ventures to develop therapeutics targeting pathogenic antibodies in autoimmune diseases.

Biohaven's investigational drug BHV-7000 failed to demonstrate statistical significance in meeting the Young Mania Rating Scale primary endpoint in a Phase II/III bipolar disorder trial.

Biohaven's NDA resubmission for troriluzole in spinocerebellar ataxia shows promise, with a 60% probability of success and potential peak sales exceeding $1 billion.

Biohaven's BHV-1400, a TRAP degrader, achieved rapid and selective lowering of aberrant Gd-IgA1 in a Phase 1 trial for IgA nephropathy.